Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

MGuard stent shows positive result in MASTER trial

InspireMD's Mguard embolic protection stent has demonstrated a positive outcome in treating patients suffering heart attacks when compared to bare metal or drug-eluting stents during the study.

The multi-center randomized MASTER (MGuard for Acute ST Elevation Reperfusion) trial has enrolled 433 patients across nine countries to evaluate the Mguard stent compared to commercially-approved bare metal or drug-eluting stents.

The Mguard embolic protection stent is a coronary stent integrated with a proprietary micronet technology that is designed to hold plaque and thrombus in place against the blocked artery’s wall.

InspireMD chief executive officer Ofir Paz said the company hase reached a milestone in the history of InspireMD.

"We look forward to presenting detailed results of the MGuard™ MASTER trial at the TCT in October," Paz added.